drugset / Trial / NCT00906373
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-10
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cixutumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | Cixutumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |